{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Canesin G"],"funding":["Industex S.L.","Vetenskapsrådet","Kungliga Fysiografiska Sällskapet i Lund","Agència de Gestió d'Ajuts Universitaris i de Recerca","Ministerio de Economía y Competitividad","Cancerfonden"],"pagination":["13958"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7434889"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(1)"],"pubmed_abstract":["Cancer stem cells (CSCs) are a small subpopulation of quiescent cells with the potential to differentiate into tumor cells. CSCs are involved in tumor initiation and progression and contribute to treatment failure through their intrinsic resistance to chemo- or radiotherapy, thus representing a substantial concern for cancer treatment. Prostate CSCs' activity has been shown to be regulated by the transcription factor Signal Transducer and Activator of Transcription 3 (STAT3). Here we investigated the effect of galiellalactone (GL), a direct STAT3 inhibitor, on CSCs derived from prostate cancer patients, on docetaxel-resistant spheres with stem cell characteristics, on CSCs obtained from the DU145 cell line in vitro and on DU145 tumors in vivo. We found that GL significantly reduced the via"],"journal":["Scientific reports"],"pubmed_title":["STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population."],"pmcid":["PMC7434889"],"funding_grant_id":["2014 SGR733","SAF2014-59958-R","18 0612","2017-01854"],"pubmed_authors":["Castellon EA","Paciucci R","Stiehm A","Contreras HR","Morote J","Maggio V","Maitland NJ","Bjartell A","Palominos M","Canesin G","Hellsten R"],"additional_accession":[]},"is_claimable":false,"name":"STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population.","description":"Cancer stem cells (CSCs) are a small subpopulation of quiescent cells with the potential to differentiate into tumor cells. CSCs are involved in tumor initiation and progression and contribute to treatment failure through their intrinsic resistance to chemo- or radiotherapy, thus representing a substantial concern for cancer treatment. Prostate CSCs' activity has been shown to be regulated by the transcription factor Signal Transducer and Activator of Transcription 3 (STAT3). Here we investigated the effect of galiellalactone (GL), a direct STAT3 inhibitor, on CSCs derived from prostate cancer patients, on docetaxel-resistant spheres with stem cell characteristics, on CSCs obtained from the DU145 cell line in vitro and on DU145 tumors in vivo. We found that GL significantly reduced the via","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2026-05-02T18:32:35.401Z","creation":"2025-04-05T11:01:12.777Z"},"accession":"S-EPMC7434889","cross_references":{"pubmed":["32811873"],"doi":["10.1038/s41598-020-70948-5"]}}